Discounted Cash Flow
Haemonetics Corp.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | $886.1m | $-26.3m | $83.6m | -3.0% | $-0.51 |
| 2018 | $903.9m (2.0%) | $45.6m (273.5%) | $145.6m (74.1%) | 5.0% (270.1%) | $0.86 (268.6%) |
| 2019 | $967.6m (7.0%) | $55.0m (20.7%) | $40.3m (-72.3%) | 5.7% (12.8%) | $1.07 (24.4%) |
| 2020 | $988.5m (2.2%) | $76.5m (39.1%) | $109.5m (171.5%) | 7.7% (36.1%) | $1.51 (41.1%) |
| 2021 | $870.5m (-11.9%) | $79.5m (3.8%) | $71.8m (-34.4%) | 9.1% (17.9%) | $1.57 (4.0%) |
| 2022 | $993.2m (14.1%) | $43.4m (-45.4%) | $75.8m (5.6%) | 4.4% (-52.2%) | $0.85 (-45.9%) |
| 2023 | $1.2b (17.7%) | $115.4m (166.1%) | $162.9m (115.0%) | 9.9% (126.1%) | $2.27 (167.1%) |
| 2024 | $1.3b (12.0%) | $117.6m (1.9%) | $115.5m (-29.1%) | 9.0% (-9.1%) | $2.32 (2.2%) |
| 2025 | $1.4b (4.0%) | $167.7m (42.6%) | $142.4m (23.4%) | 12.3% (37.2%) | $3.33 (43.5%) |
| 2026 | $1.3b (-2.0%) | $97.3m (-42.0%) | $260.4m (82.8%) | 7.3% (-40.8%) | $2.06 (-38.1%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.